Contact us Demo our platform

Metabolon @

ADPD 2025

Dates: April 1–5, 2025 
Location: Vienna, Austria (Hybrid Conference) 
Visit the Official Event Website 
Booth Location: 89 

Join Metabolon at ADPD 2025 

Metabolon is attending ADPD 2025, the largest international event showcasing advances in Alzheimer’s, Parkinson’s, and related neurodegenerative diseases. This conference brings together leading neuroscientists, clinicians, and industry professionals to discuss breakthroughs in biomarker discovery, disease mechanisms, and therapeutic development. 

Where to Find Metabolon at ADPD 2025 

You can find Metabolon exhibiting at booth location 89, where several of the Metabolon team will be happy to demonstrate our metabolomics and bioinformatics solutions with you and discuss our experiences working in neurodegenerative disease research. 

About ADPD 2025 

The ADPD International Conference is a leading platform for sharing cutting-edge research in neurodegenerative diseases, providing an interdisciplinary space for scientists and industry leaders to exchange insights and foster collaborations. The conference covers the latest discoveries in molecular pathways, early diagnostics, clinical trials, and disease-modifying treatments for Alzheimer’s, Parkinson’s, and other related disorders. 

Scientific Themes and Program Highlights 

  • Neurodegenerative Biomarkers – Advancements in blood, CSF, and imaging biomarkers for early detection and disease progression monitoring. 
  • Molecular Mechanisms of Disease – Insights into protein misfolding, mitochondrial dysfunction, and neuroinflammation. 
  • Metabolomics in Neurological Disorders – The role of metabolism in disease progression, diagnosis, and therapeutic response. 
  • Gene Therapy and Drug Discovery – Innovations in therapeutic strategies for modifying disease pathology. 
  • Multiomics and Systems Biology – Integration of metabolomics, proteomics, and genomics to advance precision medicine in neurology. 

View the Scientific Program 

Why Metabolon is Attending ADPD 2025 

Metabolon is returning to ADPD 2025 after a high-impact scientific program at ADPD 2024 in Lisbon, Portugal. There has never been a better time to generate high-quality, actionable insights from metabolomics data, and neurological research is at the forefront of new, metabolite-led biological discoveries. 

Advancements in metabolite identification, pathway mapping, and data integration have made metabolomics an essential tool for understanding neurodegenerative diseases. Metabolon provides best-in-class metabolomics solutions, delivering: 

  • Comprehensive data generation and validation through targeted and untargeted metabolomics. 
  • Seamless integration of metabolomics and other omics data within our Integrated Bioinformatics Platform. 
  • Actionable insights for biomarker discovery, drug development, and patient stratification in Alzheimer’s and Parkinson’s research. 
  • High-quality, reproducible metabolomics data supporting multiomics research and clinical translation. 

By leveraging our global expertise, validated methodologies, and extensive publication record, Metabolon’s multiomics-driven approach is a game-changer for neurodegenerative disease research.  

Meet the Metabolon Team at ADPD 2025 

Our team of scientific and business leaders will be available for discussions on how metabolomics is advancing neurodegenerative disease research: 

  • Dr. Patrick Arnott, Sales & Business Development Director, Metabolon 
    Patrick has a strong background in commercializing life sciences solutions, with expertise in DNA nanotechnology, CRISPR, vaccines, and cell & gene therapy research. His experience in biotech consulting, business strategy, and process development makes him a valuable resource for translating research needs into metabolomics-driven solutions. 
    Connect with Patrick on LinkedIn 
  • Simone de Faria Maraschin, PhD, EMEA & APAC Sales Director, Metabolon 
    Simone has over 20 years of experience in biological research, project management, and scientific solutions development. With a PhD from Leiden University, she leads Metabolon’s EMEA and APAC Sales Organization, providing strategic insights into metabolomics applications in neurological disease research. 
    Connect with Simone on LinkedIn 
  • Dr. Natasa Giallourou, Metabolomics Scientist, Metabolon 
    Natasa is a field metabolomics scientist specializing in biopharma and academic applications of metabolomics. She has a PhD from the University of Reading, with expertise in multiomics data integration, biomarker discovery, and metabolic phenotyping for complex diseases. 
    Connect with Natasa on LinkedIn 
  • Kieran Jones, Strategic Account Manager, Metabolon 
    Kieran brings extensive experience in biopharma, analytical sciences, and drug discovery. His expertise in immunoassay-based analytical method development, biomarker validation, and multiomics integration makes him a key resource for researchers looking to leverage metabolomics for therapeutic development. 
    Connect with Kieran on LinkedIn 
  • Michael Irwin, VP Sales, Metabolon 
    Michael leads Metabolon’s global sales team, supporting life sciences organizations in leveraging metabolomics for breakthrough discoveries in neurological research. Michael previously lead Olink’s Sales and Marketing departments before joining Metabolon to support the growing demand for metabolomics data insights. 
    Connect with Michael on LinkedIn 

Schedule a Meeting

Latest Resources

Access a wealth of valuable resources to deepen your understanding about metabolomics and the scientific advancements it has empowered.

✕

References

1. Zgoda-Pols, J.R., et al., Metabolomics analysis reveals elevation of 3-indoxyl sulfate in plasma and brain during chemically-induced acute kidney injury in mice: investigation of nicotinic acid receptor agonists. Toxicol Appl Pharmacol, 2011. 255(1): p. 48-56.

2. Bryant, J.A., et al., The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiome. Nat Med, 2026. 32(1): p. 186-196

3. McGovern, B .H., et al., SER-109, an Investigational Microbiome Drugto Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial. Clin Infect Dis, 2021. 72(12): p. 2132-2140.

4. Feuerstadt, P., et al., SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection. N Engl J Med, 2022. 386(3): p. 220-229.

5. Hu, Z., et al., Targeted metabolomics reveals novel diagnostic biomarkers for colorectal cancer. Mol Oncol, 2025. 19(6): p. 1737-1750.

6. Butler, F.M., et al., Vegetarian Dietary Patterns and Diet-Related Metabolites Are Associated With Kidney Function in the Adventist Health Study-2 Cohort. J Ren Nutr, 2025.

7. Stanford, J., et al., Metabolomic Profiling and Diet Quality Scoring in a Randomized Crossover Trial of Healthy and Typical Dietary Patterns. Mol Nutr Food Res, 2025 . 69(23): p. e70271.

8. O’Connor, L.E., et al., Metabolomic Profiling of an Ultraprocessed Dietary Pattern in a Domiciled Randomized Controlled Crossover Feeding Trial. J Nutr, 2023. 153(8): p. 2181-2192.

9. Fritsch, D.A., et al., Microbiome function underpins the efficacy of a fiber-supplemented dietary intervention in dogs with chronic large bowel diarrhea. BMC Vet Res, 2022. 18(1): p. 245.

10. Leal, L.N., et al., Preweaning nutrient supply improves lactation productivity and reduces the risk of culling in Holstein cows. J Dairy Sci, 2025. 108(6): p. 5875-5888.

11. Ahsin, M., et al., Soil and pasture health underlie improved beef nutrient density determined by untargeted metabolomics in Southern US grass finished beef systems. NPJ Sci Food, 2025. 9(1): p. 151.

12. Yin, W., et al., Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia. J Lipid Res, 2012. 53(1): p. 51-65.

13. Porter, F .D., et al., Cholesterol oxidation products are sensitive and specific blood-based biomarkers for Niemann-Pick C1 disease. Sci Transl Med, 2010. 2(56): p. 56ra81.

14. Needham, B .D., et al., Plasma and Fecal Metabolite Profiles in Autism Spectrum Disorder. Biol Psychiatry, 2021. 89(5): p. 451-462

15. Li, C., et al., Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells. J Exp Med, 2014. 211(1): p. 15-28.

16. Green, P.G., et al., Metabolic flexibility and reverse remodelling of the failing human heart. Eur Heart J, 2025. 46(25): p. 2422-2433.

17. Maekawa, H., et al., SGLT2 inhibition protects kidney function by SAM-dependent epigenetic repression of inflammatory genes under metabolic stress. J Clin Invest, 2025. 135(19).

18. Wu, D., et al., Integrated screens reveal that guanine nucleotide depletion, which is irreversible via targeting IMPDH2, inhibits pancreatic cancer and potentiates KRAS inhibition. Gut, 2026.

19. Schwerdtfeger, L.A., et al., Gut microbiota and metabolites are linked to disease progression in multiple sclerosis. Cell Rep Med, 2025. 6(4): p. 102055.

20. Wu, H., et al., Microbiome-metabolome dynamics associated with impaired glucose control and responses to lifestyle changes. Nat Med, 2025. 31(7): p. 2222-2231.

21. Jacobs, J.P., et al., Cognitive behavioral therapy for irritable bowel syndrome induces bidirectional alterations in the brain-gut-microbiome axis associated with gastrointestinal symptom improvement. Microbiome, 2021. 9(1): p. 236.

22. Pietzner, M., et al., Plasma metabolites to profile pathways in noncommunicable disease multimorbidity. Nat Med, 2021. 27(3): p. 471-479.

23. Faquih, T.O., et al., Robust Metabolomic Age Prediction Based on a Wide Selection of Metabolites. J Gerontol A Biol Sci Med Sci, 2025. 80(3).

24. Scherer, N., et al., Coupling metabolomics and exome sequencing reveals graded effects of rare damaging heterozygous variants on gene function and human traits. Nat Genet, 2025. 57(1): p. 193-205.

25. Holmes, Z.C., et al., Untargeted metabolomic analysis of human milk from healthy mothers reveals drivers of metabolite variability. Sci Rep, 2024. 14(1): p. 20827.

26. Titz, B., et al., Implications of Ocular Confounding Factors for Aqueous Humor Proteomic and Metabolomic Analyses in Retinal Diseases. Transl Vis Sci Technol, 2024. 13(6): p. 17.

27. Bloom, S.M., et al., Cysteine dependence of Lactobacillus iners is a potential therapeutic target for vaginal microbiota modulation. Nat Microbiol, 2022. 7(3): p. 434-450.

28. Leimer, E.M., et al., Lipid profile of human synovial fluid following intra-articular ankle fracture. J Orthop Res, 2017. 35(3): p. 657-666.